Meta Stock Decline Reflects Persistent AI Spending Anxiety Amid Capex and Regulatory Risks

What happened

Meta Platforms' stock is falling due to renewed investor concerns over rising artificial intelligence infrastructure spending, as reported by Barrons. This aligns with the DeepValue master report's emphasis on Meta's ambitious $115B–$135B 2026 capital expenditure guidance for AI data centers, which the market views as a high-stakes bet. The report highlights that power constraints and regulatory pressures in Europe, including DMA-related fines and potential revenue impacts, could undermine the ad cash flow funding this buildout. Recent announcements of AI investments have not alleviated fears, as site-level timelines suggest some capacity may not come online until 2028, delaying expected returns. Consequently, the stock movement underscores ongoing skepticism about Meta's ability to convert spending into usable compute without near-term monetization setbacks.

Implication

The current valuation offers limited margin of safety, as it assumes rapid AI capacity deployment and stable ad revenue, both of which face significant risks from Europe's DMA changes and potential delays. Monitoring near-term catalysts, such as Meta's next earnings update on capex guidance and site energization details, is critical to assess progress against these headwinds. If regulatory cash outflows materialize or capacity timelines slip further, free cash flow could contract, intensifying downside pressure and validating the bear case. Conversely, evidence of on-time compute deployment and resilient ad performance would support the bull scenario, but this remains uncertain. Therefore, maintaining a defensive stance until more data emerges is prudent to manage exposure to these intertwined uncertainties.

Thesis delta

The news article reinforces existing concerns from the DeepValue report without introducing new fundamental shifts, as AI spending anxiety and regulatory risks were already central to the investment thesis. However, the stock's reaction highlights market sensitivity to capex narratives and underscores the urgency of upcoming catalysts, such as filings quantifying Europe revenue impacts. No change to the core 'WAIT' rating is warranted, but vigilance on near-term updates remains essential to confirm or challenge the priced-in assumptions.